Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Balinatunfib - Sanofi

Next Previous
Drug Profile

Balinatunfib - Sanofi

Alternative Names: SAR-441566

Latest Information Update: 04 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sanofi
  • Class Amines; Anti-inflammatories; Antipsoriatics; Antirheumatics; Azabicyclo compounds; Benzimidazoles; Cyclobutanes; Fluorinated hydrocarbons; Heterocyclic compounds with 4 or more rings; Ketones; Phenyl ethers; Pyrimidines; Small molecules
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease; Ulcerative colitis
  • No development reported Inflammation
  • Discontinued Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 17 Feb 2026 Discontinued - Phase-I/II for Rheumatoid arthritis (In volunteers) in Netherlands due to efficacy issues (PO)
  • 17 Feb 2026 Discontinued - Phase-II for Psoriasis in USA, Canada, Bulgaria, Chile, China, Georgia, Czech Republic, Hungary, Japan, Mauritius, Poland, Portugal, Turkey, United Kingdom, Spain, Germany due to efficacy issues (PO)
  • 17 Feb 2026 Discontinued - Phase-II for Rheumatoid arthritis in USA, Canada, Argentina, Brazil, Chile, China, Georgia, Czech Republic, Germany, Greece, India, Japan, Mauritius, Mexico, Poland, Puerto Rico, Slovakia, South Africa, Spain due to efficacy issues (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top